Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 22, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 670,000 ordinary shares of 25 pence each.
- Purchase Price: 1,492.1 pence per share.
- Treasury Shares Held: 175,426,678 shares following the transaction.
- Shares in Issue: 5,807,348,486 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company purchased 670,000 shares on June 22, 2006, and intends to hold them in Treasury. The filing text does not provide comparative data against prior periods for this specific transaction volume or price.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the repurchase by multiplying 670,000 shares by 1,492.1 pence.
- Confirm the updated total share count (5,807,348,486 in issue) against subsequent filings to track dilution or further buybacks.
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the authorized buyback program.
- Note that this filing is a transactional report and does not contain operational or financial performance data for the period.